VIR · CIK 0001706431
What Vir Biotechnology, Inc. told the SEC could break it.
Vir's disclosures describe a clinical-stage company that has lost its one commercialized product and now leans on partners and financing. Apart from sotrovimab — whose FDA emergency-use authorization was revoked in December 2024 — it has no approved products and expects continued net losses with no significant product revenue until it completes clinical development and wins approvals. What revenue it does have is concentrated in a handful of collaboration partners, chiefly Norgine ($64.3 million in 2025) and GSK ($60.3 million in 2024), so a termination or wind-down of those relationships would sharply cut it. Its pipeline depends on outside parties too: a limited number of CDMOs and single-source suppliers for the synthetic siRNAs and raw materials it needs, alongside FDA approval and GDPR data-privacy obligations.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- no significant product revenue; continued net losses (sotrovimab EUA revoked)medium
Other than sotrovimab (whose FDA EUA was revoked in December 2024), Vir has no approved products and does not expect significant product-sales revenue until it completes clinical development and obtains approvals; it expects continued net losses, leaving it dependent on collaboration proceeds and financing.
“Other than sotrovimab, we have not obtained regulatory approval for our product candidates, and we do not expect to generate any significant revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.”
SEC filing →As of 2026
Regulatory & policy
- FDA approval/EUA dependence and GDPR data-privacy obligationsmedium
Vir's future depends on FDA and foreign approvals for its candidates (its only commercialized product, sotrovimab, had its EUA revoked), and it faces GDPR data-privacy obligations across its and its collaboration partners' EEA activities.
“The collection, use, disclosure, transfer or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR.”
SEC filing →As of 2026
Supplier concentration
- limited CDMOs / single-source suppliers for synthetic siRNAs and raw materialsmedium
Vir relies on a limited number of third-party suppliers and CDMOs to manufacture synthetic siRNAs and on single sources for certain raw materials/components; supplier delays, capacity constraints, batch failures or loss of a sole source could disrupt its development supply.
“we currently rely on a limited number of third-party suppliers and CDMOs that are able to meet our supply requirements for synthetic siRNAs. Our CDMOs could face risks in meeting our delivery time requirements or provide adequate amounts of synthetic siRNAs to meet our needs, which may include extended lead time”
SEC filing →As of 2026
Customer concentration
- revenue concentrated in a few collaboration partners (Norgine, GSK)low
Vir's revenue comes almost entirely from a handful of collaboration/license partners — Norgine ($64.3M in 2025) and GSK ($60.3M in 2024) dominated segment revenue — so termination or wind-down of these partner relationships (e.g., after the sotrovimab EUA revocation) would sharply cut revenue.
“In December 2024, the FDA revoked EUA granted to sotrovimab in May 2021.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we have previously recognized revenue from our profit-share related to sotrovimab under our definitive collaboration agreement with GSK executed in June 2020, or the 2020 GSK Agreement”
Cited →“On June 12, 2020, Brii Bio notified us of the exercise of its option to obtain exclusive rights to develop and commercialize compounds and products arising from elebsiran in the Greater China Territory. Brii Bio paid us a $20.0 million option exercise fee”
Cited →Astellas Pharma Inc.
“Under the terms of the Astellas Agreement, in the U.S., we will share profits and losses from future sales of VIR-5500 equally with Astellas, should VIR-5500 receive regulatory approval, and we will have the option to co-promote VIR-5500. Outside of the U.S., Astellas will obtain exclusive rights to commercialize VIR-5500”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch